Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, Poland.
Curr Drug Metab. 2010 Jul;11(6):494-506. doi: 10.2174/138920010791636211.
Dihydrocodeine (DHC) is a semi-synthetic analogue of codeine which was formed by the hydrogenation of the double tie in the main chain of the codeine molecule. DHC is used as an analgesic, antitussive and antidiarrhoeal agent; it is also used for the treatment of opioid addiction. Limited data is available on the relative potency of DHC to other opioids. The analgesic effect of DHC is probably twice as potent as codeine for the parenteral and slightly stronger for an oral route. DHC possesses approximately 1/6(th) of the morphine analgesic effect when drugs are administered orally. In this article pharmacokinetics, pharmacodynamics, dosing guidelines, adverse effects and clinical studies of DHC in pain management are shown with focus on cancer pain. The impact of CYP2D6 activity on DHC analgesia was discussed and a proposal of calculation equianalgesic doses of DHC to other opioids was put forward.
双氢可待因(DHC)是可待因分子主链中双键加氢形成的半合成类似物。DHC 用作镇痛药、镇咳药和止泻药;也用于治疗阿片类药物成瘾。关于 DHC 与其他阿片类药物相对效力的数据有限。DHC 的镇痛作用可能是可待因的两倍,对于肠胃外途径略强,口服途径略强。当药物口服给药时,DHC 的吗啡镇痛作用约为 1/6(th)。本文重点介绍癌症疼痛的管理,展示了 DHC 在疼痛管理中的药代动力学、药效学、给药指南、不良反应和临床研究。讨论了 CYP2D6 活性对 DHC 镇痛的影响,并提出了计算 DHC 与其他阿片类药物等效镇痛剂量的建议。